华盛顿港，纽约时间2016–04-26，生命科学的****者， Cadence和purification pall公司宣布，cadencetm分离器的商业化运营，声波（CAS）分离工艺应用在新的篇章，使用单一的文化bioprocess fluids clarification的细胞。CAS delivers*劲的收益，支持细胞和蛋白在封闭的系统中，当用户drastically centrifugation，减少成本和风险。CAS是可用的和适当的立即装运，并已在综合英语教学pall很容易与其他的生命科学产品，使bioprocessing连续。

“我们在传统单连续处理视觉的尽头2015的概念的引入使声波的波分离工艺作为一种工具，它的客户包括桥之间的差距bioreactor和下游加工的火车。***的问题是，我们有一个概念的商业fruition发布的**时间在英语和英语，使launches系列产品连续bioprocessing”说，副总裁和总经理的biopharmaceuticals egholm博士说，“时间eliminating信诚科技是真正的革命，他centrifugation文化clarification细胞减少，将缓冲区的要求在75 %，连续饲料流和文件，直接与我们的全集成的组合。”
生命科学的一个pall馏分分离工艺的**许可证是声波的波（flodesign精音速队在六月从2015 fds）。通过不同的CAS工程人员应用声波在流体的流量和countercurrent bioprocess波浪发电站，三dimensional公司在他们的nodes的陷阱。从这本leads aggregation和precipitation悬架，thereby”trapping”的简单细胞的提取。CAS是酒店的clarifying biologic许多类型的产品，包括recombinant proteins协调和修改monoclonal抗体的变异，在文化particulate浓度和细胞密度，turbidity和viability。
CAS是一个动态的语言的节奏特点的产品组合，使公司运营的要点单元工艺为中心，在连续生产的monoclonal抗体和其他recombinant proteins。leverages的节奏组合的收益的单一特征的综合利用工艺，它的结局结束，biomanufacturing控制解决方案，为客户productivity和降低风险。

英文原文：

PORT WASHINGTON, N.Y. – April 26, 2016 – Pall Life Sciences Biopharmaceutical division of global filtration, separation, and purification leader Pall Corporation, is pleased to announce the commercial launch of the CadenceTM Acoustic Separator (CAS), which applies acoustic wave separation technology in a novel single-use format for the clarification of cell culture bioprocess fluids. The CAS delivers robust, reliable cell and protein yields in a closed system without centrifugation, while drastically reducing user cost and risk. The CAS is available for immediate ordering and shipment, and has also been designed to be easily integrated with other Pall Life Sciences products to enable continuous bioprocessing.

“We launched our continuous processing vision at the end of 2015, introducing the concept of acoustic wave separation technology as an enabling tool for customers to bridge the critical gap between the bioreactor and the downstream processing train. We have now brought that concept to fruition with the commercial launch of the CAS as the first in a series of product launches that enable continuous bioprocessing,” said Vice President and General Manager of Biopharmaceuticals, Michael Egholm, Ph.D. “The CAS technology is truly revolutionary, eliminating reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and creating a continuous feed stream for direct integration with our full portfolio.”

Pall Life Sciences obtained an exclusive license to acoustic wave separation technology in June 2015 from FloDesign Sonics (FDS). The CAS works via acoustic forces that are applied across a countercurrent flow of bioprocess fluid, generating three-dimensional standing waves that trap cells at their nodes. This leads to aggregation and precipitation from suspension, thereby “trapping” the cells for simple extraction. The CAS is capable of clarifying many types of biologic products, including recombinant therapeutic proteins and monoclonal antibodies, regardless of the variability in particulate concentrations and cell culture density, turbidity and viability.

The CAS is part of the Cadence product portfolio, which features enabling technologies for key unit operations required in the continuous production of monoclonal antibodies and other recombinant proteins. The Cadence portfolio leverages the benefits of single-use technologies to feature integrated, end to end biomanufacturing solutions that increase productivity and decrease risk for customers.